3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
5
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Hodgkin Disease
47
Lymphoma
22
Lymphoma, Non-Hodgkin
18
Lymphoma, Large B-Cell, Diffuse
15
Multiple Myeloma
12
Melanoma
9
Lymphoma, B-Cell
9
Leukemia, Lymphocytic, Chronic, B-Cell
9
Hematologic Neoplasms
9
Lymphoma, Follicular
7
Myelodysplastic Syndromes
5
Mycosis Fungoides
5
Lymphoma, T-Cell, Peripheral
5
Lymphoma, T-Cell
5
Lymphoma, Large-Cell, Anaplastic
5
Carcinoma, Renal Cell
5
Burkitt Lymphoma
5
Uterine Cervical Neoplasms
4
Recurrence
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasm Metastasis
4
Lymphoma, T-Cell, Cutaneous
4
Lymphoma, B-Cell, Marginal Zone
4
Colorectal Neoplasms
4
Carcinoma, Merkel Cell
4
Breast Neoplasms
4
Stomach Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Pancreatic Neoplasms
3
Interventions
X-Rays
6
Phantoms, Imaging
6
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
Nuclear Medicine Department, Hospital
5
Biopsy
4
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
olaparib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
Vemurafenib
2
Temozolomide
2
LY3023414
2
Filgrastim
2
trametinib
1
sonidegib
1
sargramostim
1
ribociclib
1
entinostat
1
dostarlimab
1
carboxyamido-triazole
1
bempegaldesleukin
1
Thalidomide
1
Pharmacogenomic Variants
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ependymoma
×
Nivolumab
×
Lymphoid
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts